Skip to Content

Zanosar (streptozocin) Disease Interactions

There are 4 disease interactions with Zanosar (streptozocin):

Major

Streptozocin (applies to Zanosar) hepatic dysfunction

Major Potential Hazard, Low plausibility. Applicable conditions: Liver Disease

Unspecified hepatic dysfunction has been noted during streptozocin therapy. The pharmacokinetic disposition of streptozocin has not been extensively studied. Therapy with streptozocin should be administered cautiously in patients with a history or predisposition to compromised hepatic function. Liver function tests should be done at least weekly and dosage adjustments or discontinuance of therapy may be indicated, depending upon the degree of toxicity noted.

References

  1. "Product Information. Zanosar (streptozocin)." Pharmacia and Upjohn, Kalamazoo, MI.
Major

Streptozocin (applies to Zanosar) myelosuppression

Major Potential Hazard, Low plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Streptozocin therapy causes hematologic toxicity and some cases of severe leukopenia and thrombocytopenia have resulted in death. Therapy with streptozocin should be administered cautiously in patients with bone marrow suppression. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Zanosar (streptozocin)." Pharmacia and Upjohn, Kalamazoo, MI.
Major

Streptozocin (applies to Zanosar) renal dysfunction

Major Potential Hazard, High plausibility.

Renal toxicity reported during streptozocin therapy is dose-related, cumulative, and may be severe or fatal. The use of streptozocin in patients with renal disease requires a judgment by the physician of potential benefit as opposed to the known risk of serious renal damage. If the need outweighs the risk, extreme caution should be exercised in administering streptozocin and therapy should be initiated at a reduced dosage. Close clinical monitoring of renal function such as serial urinalysis, BUN, serum creatinine, creatinine clearance, and serum electrolytes prior to and after each course of streptozocin therapy is recommended. Development of significant renal toxicity may require a reduction in dose or discontinuation of streptozocin therapy.

References

  1. "Product Information. Zanosar (streptozocin)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. Perry DJ, Weiss RB "Nephrotoxicity of streptozocin." Ann Intern Med 96 (1982): 122
Moderate

Streptozocin (applies to Zanosar) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Mild to moderate abnormalities of glucose tolerance have been noted in some patients treated with streptozocin. These have generally been reversible, but insulin shock with hypoglycemia has been observed. Caution is recommended when using this agent in diabetic patients, and close monitoring of blood sugar levels is recommended during therapy.

Zanosar (streptozocin) drug interactions

There are 209 drug interactions with Zanosar (streptozocin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.